Achillion Announces Nicole Vitullo Elected to Chair the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
19
Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors

NEW HAVEN, Conn., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system, today announced that the Company’s Board of Directors has elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain Associates LLC and has been a member of Achillion's Board of Directors since September 2010. As Chair, she replaces David Scheer, who has served on the Achillion Board since 1998 and was elected Chair in March 2010.  Mr. Scheer will remain on the Board of Directors of the Company.

“Nicole’s successful track record and experience advising and helping grow public healthcare companies makes her an excellent choice for this leadership position as we continue to advance Achillion,” said Mr. Scheer. “We believe Achillion is well positioned to drive its complement factor D inhibitor programs into late-stage development and achieve its goal to offer patients new and innovative treatments for immune-related diseases associated with the complement alternative pathway.”

Ms. Vitullo, commented, “Achillion is an exciting clinical stage biopharmaceutical company with a compelling and promising platform. I am honored to serve as Chair and look forward to working with David, the other Board members and the Achillion management team to create both near-term and long-term value for our shareholders. I would also like to thank David for his leadership and his significant contributions to Achillion throughout his tenure.”

Ms. Vitullo serves as a partner at Domain Associates LLC, a healthcare-focused private equity firm. For more than a decade, Ms. Vitullo was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. Ms. Vitullo joined Domain Associates in 1999 and became a Partner in 2004. Prior to Domain, she was senior vice president at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. Ms. Vitullo currently also serves on the Board of Directors of Celtaxsys, Esperion Therapeutics, Marinus Pharmaceuticals and Antios Therapeutics. She received a B.A. in mathematics and an MBA in finance from the University of Rochester.

About Achillion Pharmaceuticals Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Factor D is an essential enzyme in the alternative pathway of the complement system, a part of the innate immune system. Achillion is initially focusing its drug development activities on alternative pathway-mediated diseases where there are no approved therapies or where existing therapies are inadequate for patients. Potential indications being evaluated for its compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN). Each of the product candidates in the Company’s oral factor D portfolio was discovered in its laboratories and is wholly owned. To advance its investigational product candidates into Phase 3 clinical trials and commercialization, the Company plans to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. More information is available at http://www.achillion.com .

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Achillion may use words such as “expect,” “anticipate,” “project,” “target,” “intend,” “plan,” “aim,” “believe,” “seek,” “estimate,” “can,” “could” “focus,” “will,” “look forward,” “continue,” “goal,” “strategy,” “objective,” “may,” “potential,” and similar expressions to identify such forward-looking statements. These forward-looking statements also include statements about: the potential benefits of factor D inhibition as a treatment for complement-mediated diseases; the  potential benefits of, and indications for, Achillion’s compounds that inhibit factor D, including ACH-4471, ACH-5228 and ACH-5548; Achillion’s belief  that its portfolio of compounds could expand factor D portfolio opportunities, provide strategic optionality or create significant value; Achillion’s expectations regarding the advancement of, and timeline for reporting results from, clinical trials of its product candidates as well as its ability to advance additional compounds; and other statements concerning Achillion’s strategic goals, efforts, plans, and prospects. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things, Achillion’s ability to: demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its product candidates; advance the preclinical and clinical development of its complement factor D inhibitors under the timelines it projects in current and future preclinical studies and clinical trials; enroll patients in its clinical trials on its projected timelines; obtain and maintain patent protection for its product candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals, and the granting of orphan designation does not alter the standard regulatory requirements and process for obtaining such approval; establish commercial manufacturing arrangements; identify, enter into and maintain collaboration and other commercial agreements with third-parties; compete successfully in the markets in which it seeks to develop and commercialize its product candidates and future products; manage expenses; manage litigation; raise the substantial additional capital needed to achieve its business objectives; and successfully execute on its business strategies. These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2018, and any other SEC filings that Achillion makes from time to time.

In addition, any forward-looking statement in this press release represents Achillion's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Achillion disclaims any duty to update any forward-looking statement, except as required by applicable law.

Investors & Media: Brian Di Donato Vice President, Investor Relations and Corporate Communications Achillion Pharmaceuticals, Inc. Tel. (215) 709-3032 bdidonato@achillion.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 108

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 104

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitfarms and Riot Platforms Reach Important Settlement Agreement

Updated Category News Views 57

Bitfarms Ltd and Riot Platforms Reach Settlement on Disputes Today, Bitfarms Ltd (NASDAQ:BITF), a leading player in the cryptocurrency mining field, announced that it has successfully settled disputes with Riot Platforms (NASDAQ:RIOT). This important settlement seeks to resolve various conflicts that existed between the two companies, although the specific details of...

Continue Reading
Peer To Peer Network Unveils Strategic Insights for PTOP Labs

Updated Category News Views 195

Peer To Peer Network Reveals Insights on PTOP Intelligence Labs Peer To Peer Network (OTC: PTOP) has taken a decisive step towards revolutionizing investor communication and engagement with the introduction of PTOP Intelligence Labs. During a recent call, the company’s newly appointed division president, Derek McCarthy, shared insights into the innovative AI-driven...

Continue Reading
Firsthand Technology Fund Reports Third Quarter Financial Performance

Updated Category News Views 234

Firsthand Technology Value Fund Financial Overview Firsthand Technology Value Fund, Inc. (OTCQB: SVVC), a publicly trading venture capital fund focused on technology and cleantech investments, has provided an update on its financial performance for the recent quarter. As of the end of September, the Fund reported net assets amounting to $296,547, translating to $0.04 per...

Continue Reading
Nanit Unveils Innovative AI Sleep Score Tailored for Babies

Updated Category News Views 310

Nanit Launches Groundbreaking AI Sleep Score for Infants Nanit has introduced an innovative Sleep Score feature aimed specifically at helping parents enhance their babies' sleep quality. This groundbreaking technology translates complex clinical-grade sleep data into a single, easy-to-understand number. Parents will now have access to a powerful tool that demystifies...

Continue Reading
The Surge of the Manufacturing Execution System Market

Updated Category News Views 155

Introduction to the Manufacturing Execution System Market The global manufacturing execution system (MES) market is experiencing remarkable growth, fueled by the rising trend of digital transformation across various manufacturing sectors. As industries evolve, the demand for real-time data and efficient management of production processes is becoming increasingly critical....

Continue Reading